NCT05961761View on ClinicalTrials.gov

Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

January 31, 2028

Study Completion Date

December 31, 2028

Conditions
Soft Tissue Sarcoma AdultAngiosarcomaUndifferentiated Pleomorphic Sarcoma
Interventions
DRUG

Propranolol

propranolol 40 mg x2 daily

DRUG

Pembrolizumab

pembrolizumab 2 mg/kg every 3 weeks

Trial Locations (4)

2730

RECRUITING

Herlev Gentofte Hospital, Herlev

8200

NOT_YET_RECRUITING

Aarhus University Hospital, Aarhus

Unknown

RECRUITING

Oslo University Hospital, Oslo

NOT_YET_RECRUITING

Karolinska University Hospital, Stockholm

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

collaborator

Oslo University Hospital

OTHER

collaborator

Karolinska University Hospital

OTHER

lead

Niels Junker

OTHER